ArticlePloS one2025
Limited sensitivity of somatosensory evoked potentials as disease monitoring biomarkers in hereditary spastic paraplegias.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHereditary Spastic Paraplegias (HSP) are a group of genetic disorders leading to the degeneration of long motor and sensory tracts in a progressive course. Clinician-reported outcomes (ClinROs) are the most commonly used endpoints for monitoring these diseases, but they have low sensitivity to detect progression. Therefore, identifying new monitoring biomarkers with higher sensitivity to change is crucial. Our objective was to compare the progression of Somatosensory Evoked Potential (SSEP) latencies over time with ClinROs in HSP.
methodsA longitudinal study was conducted on 22 individuals with a genetic diagnosis (13 SPG4, 3 SPG5, 3 SPG7, 2 SPG10, and 1 cerebrotendinous xanthomatosis), with two evaluations over a 4-year interval of upper limb (UL) and lower limb (LL) SSEPs and the Spastic Paraplegia Rating Scale (SPRS) total score and motor items only (mSPRS).
resultsIn the follow-up time analysis, progression after 4 years was observed only for SPRS and mSPRS, with an annual progression of 1.12 points and 1.02 points, respectively. No statistically significant progression was observed for SSEPs. Disease progression modeled according to disease duration showed worsening in all outcomes. For each additional year of disease, the SPRS worsened by 0.834 points (95% CI 0.62 to 1.04, p < 0.001), mSPRS by 0.758 points (95% CI 0.55 to 0.96, p < 0.001), SSEP-UL latency by 0.164 ms (95% CI 0.03 to 0.3, p < 0.001), and SSEP-LL latency by 1.343 ms (95% CI 0.74 to 1.93, p < 0.001). Results for the SPG4 subgroup were similar to those for the overall HSP group.
conclusionThe neurophysiological progression of sensory long tract dysfunction is even slower than the progression of motor findings measured by COAs in HSP. The low sensitivity to change of SSEPs identified suggests that they should not be used as primary endpoints in future clinical trials for disease-modifying drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.